HK inno.N Valuation
Is A195940 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A195940 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A195940 (₩38400) is trading above our estimate of fair value (₩9045.62)
Significantly Below Fair Value: A195940 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A195940?
Key metric: As A195940 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A195940's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | ₩1.16t |
| Market Cap | ₩1.09t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A195940's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.7x | ||
A214370 Caregen | 5.3x | 13.6% | ₩1.2t |
A185750 Chong Kun Dang Pharmaceutical | 1.3x | -16.7% | ₩1.2t |
A140410 Mezzion PharmaLtd | 17.1x | n/a | ₩919.9b |
A039200 Oscotec | 7x | 132.4% | ₩922.5b |
A195940 HK inno.N | n/a | 20.5% | ₩1.1t |
Price-To-Book vs Peers: Insufficient data to calculate A195940's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does A195940's PB Ratio compare vs other companies in the KR Pharmaceuticals Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: Insufficient data to calculate A195940's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is A195940's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A195940's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₩38,400.00 | ₩62,166.67 +61.9% | 10.1% | ₩70,000.00 | ₩49,000.00 | n/a | 12 |
| Nov ’25 | ₩47,050.00 | ₩62,166.67 +32.1% | 10.1% | ₩70,000.00 | ₩49,000.00 | n/a | 12 |
| Oct ’25 | ₩48,850.00 | ₩57,636.36 +18.0% | 10.6% | ₩70,000.00 | ₩49,000.00 | n/a | 11 |
| Sep ’25 | ₩48,000.00 | ₩54,727.27 +14.0% | 6.0% | ₩61,000.00 | ₩49,000.00 | n/a | 11 |
| Aug ’25 | ₩40,100.00 | ₩54,583.33 +36.1% | 5.7% | ₩61,000.00 | ₩49,000.00 | n/a | 12 |
| Jul ’25 | ₩38,500.00 | ₩53,916.67 +40.0% | 6.4% | ₩61,000.00 | ₩49,000.00 | n/a | 12 |
| Jun ’25 | ₩38,650.00 | ₩53,916.67 +39.5% | 6.4% | ₩61,000.00 | ₩49,000.00 | n/a | 12 |
| May ’25 | ₩38,750.00 | ₩53,750.00 +38.7% | 6.9% | ₩61,000.00 | ₩48,000.00 | n/a | 12 |
| Apr ’25 | ₩37,650.00 | ₩53,916.67 +43.2% | 7.3% | ₩61,000.00 | ₩48,000.00 | n/a | 12 |
| Mar ’25 | ₩38,300.00 | ₩54,090.91 +41.2% | 7.5% | ₩61,000.00 | ₩48,000.00 | n/a | 11 |
| Feb ’25 | ₩41,200.00 | ₩54,090.91 +31.3% | 7.5% | ₩61,000.00 | ₩48,000.00 | n/a | 11 |
| Jan ’25 | ₩44,450.00 | ₩52,222.22 +17.5% | 5.6% | ₩57,000.00 | ₩48,000.00 | n/a | 9 |
| Dec ’24 | ₩40,150.00 | ₩51,777.78 +29.0% | 4.7% | ₩55,000.00 | ₩48,000.00 | n/a | 9 |
| Nov ’24 | ₩43,500.00 | ₩51,222.22 +17.8% | 4.3% | ₩55,000.00 | ₩48,000.00 | ₩47,050.00 | 9 |
| Oct ’24 | ₩42,100.00 | ₩46,333.33 +10.1% | 7.7% | ₩51,000.00 | ₩38,000.00 | ₩48,850.00 | 9 |
| Sep ’24 | ₩36,300.00 | ₩45,125.00 +24.3% | 6.5% | ₩48,000.00 | ₩38,000.00 | ₩48,000.00 | 8 |
| Aug ’24 | ₩32,900.00 | ₩45,555.56 +38.5% | 7.5% | ₩52,000.00 | ₩38,000.00 | ₩40,100.00 | 9 |
| Jul ’24 | ₩30,050.00 | ₩46,666.67 +55.3% | 8.3% | ₩52,000.00 | ₩38,000.00 | ₩38,500.00 | 9 |
| Jun ’24 | ₩33,850.00 | ₩46,666.67 +37.9% | 8.3% | ₩52,000.00 | ₩38,000.00 | ₩38,650.00 | 9 |
| May ’24 | ₩32,250.00 | ₩47,375.00 +46.9% | 9.7% | ₩53,000.00 | ₩38,000.00 | ₩38,750.00 | 8 |
| Apr ’24 | ₩34,100.00 | ₩50,625.00 +48.5% | 4.2% | ₩53,000.00 | ₩46,000.00 | ₩37,650.00 | 8 |
| Mar ’24 | ₩36,450.00 | ₩50,625.00 +38.9% | 4.2% | ₩53,000.00 | ₩46,000.00 | ₩38,300.00 | 8 |
| Feb ’24 | ₩39,650.00 | ₩51,428.57 +29.7% | 6.6% | ₩58,000.00 | ₩46,000.00 | ₩41,200.00 | 7 |
| Jan ’24 | ₩37,050.00 | ₩51,285.71 +38.4% | 6.5% | ₩58,000.00 | ₩46,000.00 | ₩44,450.00 | 7 |
| Dec ’23 | ₩38,100.00 | ₩52,000.00 +36.5% | 7.0% | ₩58,000.00 | ₩46,000.00 | ₩40,150.00 | 8 |
| Nov ’23 | ₩36,400.00 | ₩52,500.00 +44.2% | 5.7% | ₩58,000.00 | ₩50,000.00 | ₩43,500.00 | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Bioneer
₩515.2b
Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.
A064550
₩19,960.00
7D
0.3%
1Y
-33.5%
J2KBIO
₩53.4b
A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.
A420570
₩9,340.00
7D
1.7%
1Y
n/a
Hugel
₩2.9t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩260,000.00
7D
-4.1%
1Y
69.9%